Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immunotherapy
Pharma
AZ, GSK make case for broad I-O uses in endometrial cancer
For AstraZeneca's and GSK's PD-(L)1/PARP regimens, the contribution of a PARP drug in a subset of endometrial cancer patients have come into question.
Angus Liu
Mar 18, 2024 11:05am
Exelixis joins Novartis on FDA waiting list in prostate cancer
Jan 25, 2024 8:00am
BMS shows I-O duo's power in first-line colorectal cancer
Jan 20, 2024 10:00am
Sanofi back on M&A trail with $2.9B deal for Provention
Mar 13, 2023 9:18am
VacV exits stealth with systemic oncolytic viral delivery tech
Oct 31, 2022 9:15am
Coherus and Junshi's cancer immunotherapy has stalled at the FDA
May 3, 2022 8:02am